• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    MoonLake Shares In Focus After Wider Third Quarter Loss at MoonLake Immunotherapeutics (MLTX)

    Simply Wall St·11/10/2026 00:37:29
    Listen to the news
    • MoonLake Immunotherapeutics reported third quarter 2026 results with a net loss of US$79.55 million and basic and diluted loss per share of US$0.93, compared with a loss of US$69.73 million and US$1.10 per share in the prior year period.
    • For the first nine months of 2026, management recorded a net loss of US$211.06 million and a basic and diluted loss per share of US$2.74, highlighting the cash and execution demands of advancing sonelokimab through late stage development without any reported revenue yet.
    • The next step is to assess how MoonLake Immunotherapeutics' investment narrative around sonelokimab and potential future HS-related cash flows aligns with a larger year-to-date loss.

    Compare MoonLake Immunotherapeutics' high cash burn profile with other late stage biotechs by scanning our hand picked list of 19 high quality undiscovered gems.

    MoonLake Immunotherapeutics Investment Narrative Recap

    To own MoonLake Immunotherapeutics, you need to believe sonelokimab can move from a single late stage asset into a broader franchise across hidradenitis suppurativa and other inflammatory conditions. The recent quarterly figures reinforce what you already know. This is a pre revenue biotech that lives on cash, trial execution, and regulatory progress rather than earnings.

    The analyst consensus Narrative on Simply Wall St still points to HS approval and launch as the key near term catalyst, supported by the planned BLA submission and eventual commercial entry. The larger year to date loss simply underlines the main risk. MoonLake Immunotherapeutics may need more external funding if timelines slip or spending rises.

    The fresh earnings update is the announcement that matters most right now. A net loss of US$79.55 million in the third quarter and US$211.06 million across the first nine months of 2026 gives you a clearer view of the burn rate needed to push sonelokimab through late stage work without any reported revenue.

    These figures sit alongside earlier capital moves and supply commitments highlighted in the analyst consensus Narrative on Simply Wall St. When you line them up with the planned HS regulatory milestones, the picture is straightforward. Progress on the BLA and indication expansion represents the upside case, while future dilution and potential supply related costs remain the key operational overhangs.

    MoonLake Immunotherapeutics' narrative projects US$289.4 million of revenue and US$49.9 million of earnings by 2029. This implies a move from no revenue today, with earnings increasing by about US$313.6 million from the current loss of US$263.7 million to the forecast 2029 consensus figure.

    Uncover why MoonLake Immunotherapeutics' fair value indicates a 126% potential upside to its current price, which could narrow quickly if sentiment shifts.

    NasdaqCM:MLTX 1-Year Stock Price Chart
    NasdaqCM:MLTX 1-Year Stock Price Chart

    Exploring Other Perspectives

    One bearish twist on MoonLake Immunotherapeutics focuses on real world uptake risk. The most pessimistic analysts were only pencilling in US$23.5 million of revenue and about US$4.0 million of earnings by 2029 before this earnings release. That reflects a far slower adoption curve, so you may wish to use these lower forecasts to pressure test your own view.

    Explore another MoonLake Immunotherapeutics fair value estimate, including one that suggests it could be worth just $28.54!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view.

    Looking For More Investment Ideas Beyond MoonLake Immunotherapeutics?

    If MoonLake Immunotherapeutics has sharpened your sense of risk and reward in high uncertainty situations, it can help to compare it with a wider watchlist of businesses at different stages of maturity. The Simply Wall St Screener lets you quickly filter for traits that match how you like to invest, whether that means steadier balance sheets, potential mispricing, or under the radar opportunities.